Diuretic and Anti-hyperuricemic Effects of Geranyl Acetate in Rats.

Antioxidant activity gout hypertension hyperuricemia natural products nitric oxide xanthine oxidase.

Journal

Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157

Informations de publication

Date de publication:
04 Sep 2024
Historique:
received: 09 01 2024
revised: 12 06 2024
accepted: 12 06 2024
medline: 5 9 2024
pubmed: 5 9 2024
entrez: 5 9 2024
Statut: aheadofprint

Résumé

Geranyl acetate, a compound found in plant oils, has been studied for its potential effects on renal and cardiovascular ailments. This study aimed to investigate the diuretic and anti-hyperuricemic properties of geranyl acetate in male Wistar rats using a hyperuricemia-induced rat model. Molecular docking studies were conducted to assess geranyl acetate's interactions with various targets. in vitro studies were performed to evaluate its scavenging ability and inhibition of xanthine oxidase, urease, and acetylcholinesterase. Subsequently, we administered different doses of geranyl acetate (25, 50, and 100 mg/kg) and a reference drug (furosemide) to the rats to assess their acute and repeated dose diuretic effects over seven days. To understand the diuretic mechanism, we used inhibitors, such as L-- NAME, indomethacin, and atropine, prior to administering geranyl acetate. We also tested the anti-hyperuricemic potential of geranyl acetate on hyperuricemic rats. Molecular docking suggested strong binding between geranyl acetate and nitric oxide synthase. in vitro studies showed significant free radical scavenging activity and and inhibition of acetylcholinesterase, xanthine oxidase, and urease. The 100 mg/kg dose exhibited the most promising diuretic effects, with nitric oxide appearing to influence its action. Uric acid excretion increased at this dose, resembling allopurinol effects. Geranyl acetate has demonstrated significant diuretic and anti-hyperuricemic effects, likely influenced by nitric oxide release and inhibition of enzymes, like xanthine oxidase and urease. The findings have suggested potential benefits for individuals with kidney ailments, hypertension, and gout.

Sections du résumé

BACKGROUND BACKGROUND
Geranyl acetate, a compound found in plant oils, has been studied for its potential effects on renal and cardiovascular ailments.
OBJECTIVE OBJECTIVE
This study aimed to investigate the diuretic and anti-hyperuricemic properties of geranyl acetate in male Wistar rats using a hyperuricemia-induced rat model.
METHODS METHODS
Molecular docking studies were conducted to assess geranyl acetate's interactions with various targets. in vitro studies were performed to evaluate its scavenging ability and inhibition of xanthine oxidase, urease, and acetylcholinesterase. Subsequently, we administered different doses of geranyl acetate (25, 50, and 100 mg/kg) and a reference drug (furosemide) to the rats to assess their acute and repeated dose diuretic effects over seven days. To understand the diuretic mechanism, we used inhibitors, such as L-- NAME, indomethacin, and atropine, prior to administering geranyl acetate. We also tested the anti-hyperuricemic potential of geranyl acetate on hyperuricemic rats.
RESULTS RESULTS
Molecular docking suggested strong binding between geranyl acetate and nitric oxide synthase. in vitro studies showed significant free radical scavenging activity and and inhibition of acetylcholinesterase, xanthine oxidase, and urease. The 100 mg/kg dose exhibited the most promising diuretic effects, with nitric oxide appearing to influence its action. Uric acid excretion increased at this dose, resembling allopurinol effects.
CONCLUSION CONCLUSIONS
Geranyl acetate has demonstrated significant diuretic and anti-hyperuricemic effects, likely influenced by nitric oxide release and inhibition of enzymes, like xanthine oxidase and urease. The findings have suggested potential benefits for individuals with kidney ailments, hypertension, and gout.

Identifiants

pubmed: 39234901
pii: CMC-EPUB-142804
doi: 10.2174/0109298673300632240823061848
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Sarmad Nawaz Shah (SN)

Department of Pharmacology, Faculty of Pharmacy, The University of Lahore, Lahore, Pakistan.

Waqas Younis (W)

Department of Pharmacology, Faculty of Pharmacy, The University of Lahore, Lahore, Pakistan.
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University Grossman School of Medicine, USA.

Arquimedes Gasparotto Junior (AG)

Laboratory of Cardiovascular Pharmacology, Faculty of Health Sciences, Federal University of Grande Dourados, Dourados, Brazil.

Wajiha Manzoor (W)

Department of Pharmacology, Faculty of Pharmacy, The University of Lahore, Lahore, Pakistan.

Muhammad Nasir Hayat Malik (MNH)

Faculty of Pharmacy, Capital University of Science and Technology, Islamabad, Pakistan.

Muhammad Naveed Mushtaq (MN)

Department of Pharmacology, Faculty of Pharmacy, The University of Lahore, Lahore, Pakistan.

Muhammad Usman Munir (MU)

Australian Institute for Bioengineering & Nanotechnology, The University of Queensland, Brisbane Australia.

Asifa Bashir (A)

Riphah Institute of Pharmaceutical Sciences, Riphah International University, Lahore, Pakistan.

Shabana Bibi (S)

Department of Biosciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan.

Muhammad Talha (M)

Department of Pharmacology, Faculty of Pharmacy, The University of Lahore, Lahore, Pakistan.

Francislaine Aparecida Dos Reis Livero (FADR)

Laboratory of Cardiometabolic Pharmacology, Federal University of Paraná, Curitiba, Brazil and Laboratory of Preclinical Research of Natural Products, Paranaense University, Umuarama, Brazil.

Classifications MeSH